-
Abbink P, Larocca RA, Ra DLB, Bricault CA, Moseley ET, Boyd M, Kirilova M, Li Z, Ng'Ang'A D, Nanayakkara O, 2016: Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys[J]. Science, 353, 1129-. doi: 10.1126/science.aah6157
-
Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, Yerly S, Dayer JA, Kraehling V, Kasonta R, 2016: Phase 1 trials of rVSV Ebola vaccine in Africa and Europe[J]. N Engl J Med, 374, 1647-1660. doi: 10.1056/NEJMoa1502924
-
Boigard H, Alimova A, Martin GR, Katz A, Gottlieb P, Galarza JM, 2017: Zika virus-like particle (VLP) based vaccine[J]. PLoS Negl Trop Dis, 11, e0005608-. doi: 10.1371/journal.pntd.0005608
-
Cao-Lormeau VM, Blake A, Mons S, Lastere S, Roche C, Vanhomwegen J, Dub T, Baudouin L, Teissier A, Larre P, 2016: Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study[J]. Lancet, 387, 1531-1539. doi: 10.1016/S0140-6736(16)00562-6
-
Cobleigh MA, Wei X, Robek MD, 2013: A vesicular stomatitis virus-based therapeutic vaccine generates a functional CD8 T cell response to hepatitis B virus in transgenic mice[J]. J Virol, 87, 2969-2973. doi: 10.1128/JVI.02111-12
-
Gagnon SJ, Zeng W, Kurane I, Ennis FA, 1996: Identification of two epitopes on the dengue 4 virus capsid protein recognized by a serotypespecific and a panel of serotype-cross-reactive human CD4+ cytotoxic T-lymphocyte clones[J]. J Virol, 70, 141-147.
-
Geisbert TW, Daddario-Dicaprio KM, Geisbert JB, Reed DS, Feldmann F, Grolla A, Stroher U, Fritz EA, Hensley LE, Jones SM, Feldmann H, 2008: Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses[J]. Vaccine, 26, 6894-6900. doi: 10.1016/j.vaccine.2008.09.082
-
Gil L, Izquierdo A, Lazo L, Valdes I, Ambala P, Ochola L, Marcos E, Suzarte E, Kariuki T, Guzman G, Guillen G, Hermida L, 2014: Capsid protein: evidences about the partial protective role of neutralizing antibody-independent immunity against dengue in monkeys[J]. Virology 456-, 457, 70-76.
-
Guzman MG, Harris E, 2015: Dengue[J]. Lancet, 385, 453-465. doi: 10.1016/S0140-6736(14)60572-9
-
Heukelbach J, Alencar CH, Kelvin AA, de Oliveira WK, de Goes Pamplona, Cavalcanti L, 2016: Zika virus outbreak in Brazil[J]. J Infect Dev Ctries, 10, 116-120. doi: 10.3855/jidc.8217
-
Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, Grolla A, Klenk HD, Sullivan NJ, Volchkov VE, Fritz EA, Daddario KM, Hensley LE, Jahrling PB, Geisbert TW, 2005: Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses[J]. Nat Med, 11, 786-790. doi: 10.1038/nm1258
-
Kahn JS, Roberts A, Weibel C, Buonocore L, Rose JK, 2001: Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge[J]. J Virol, 75, 11079-11087. doi: 10.1128/JVI.75.22.11079-11087.2001
-
Kapadia SU, Rose JK, Lamirande E, Vogel L, Subbarao K, Roberts A, 2005: Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine[J]. Virology, 340, 174-182. doi: 10.1016/j.virol.2005.06.016
-
Kawiecki AB, Christofferson RC, 2016: Zika virus-induced antibody response enhances dengue virus serotype 2 replication in vitro[J]. J Infect Dis, 214, 1357-1360. doi: 10.1093/infdis/jiw377
-
Larocca RA, Abbink P, Peron JP, Zanotto PM, Iampietro MJ, Badamchi-Zadeh A, Boyd M, Ng'ang'a D, Kirilova M, Nityanandam R, 2016a: Vaccine protection against Zika virus from Brazil[J]. Nature, 536, 474-478. doi: 10.1038/nature18952
-
Larocca RA, Abbink P, Peron JPS, Zanotto PMDA, Iampietro MJ, Badamchi-Zadeh A, Boyd M, Ng'ang'a AD, Kirilova M, Nityanandam R, 2016b: Vaccine protection against Zika virus from Brazil[J]. Nature, 536, 474-. doi: 10.1038/nature18952
-
Lawson ND, Stillman EA, Whitt MA, Rose JK, 1995: Recombinant vesicular stomatitis viruses from DNA[J]. Proc Natl Acad Sci USA, 92, 4477-4481. doi: 10.1073/pnas.92.10.4477
-
Lazear HM, Diamond MS, 2016: Zika virus: new clinical syndromes and its emergence in the Western Hemisphere[J]. J Virol, 90, 4864-4875. doi: 10.1128/JVI.00252-16
-
Lazo L, Hermida L, Zulueta A, Sanchez J, Lopez C, Silva R, Guillen G, Guzman MG, 2007: A recombinant capsid protein from Dengue-2 induces protection in mice against homologous virus[J]. Vaccine, 25, 1064-1070. doi: 10.1016/j.vaccine.2006.09.068
-
Liu X, Qu L, Ye X, Yi C, Zheng X, Hao M, Su W, Yao Z, Chen P, Zhang S, Feng Y, Wang Q, Yan Q, Li P, Li H, Li F, Pan W, Niu X, Xu R, Feng L, Chen L, 2018: Incorporation of NS1 and prM/M are important to confer effective protection of adenovirus-vectored Zika virus vaccine carrying E protein[J]. NPJ Vaccines, 3, 29-. doi: 10.1038/s41541-018-0072-6
-
Ming GL, Tang H, Song H, 2016: Advances in Zika virus research: stem cell models, challenges, and opportunities[J]. Cell Stem Cell, 19, 690-702. doi: 10.1016/j.stem.2016.11.014
-
Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, Dowd KA, Sutherland LL, Scearce RM, Parks R, 2017: Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination[J]. Nature, 543, 248-251. doi: 10.1038/nature21428
-
Reuter JD, Vivas-Gonzalez BE, Gomez D, Wilson JH, Brandsma JL, Greenstone HL, Rose JK, Roberts A, 2002: Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease[J]. J Virol, 76, 8900-8909. doi: 10.1128/JVI.76.17.8900-8909.2002
-
Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, Julander JG, Tang WW, Shresta S, Pierson TC, Ciaramella G, Diamond MS, 2017: Modified mRNA vaccines protect against Zika virus infection[J]. Cell, 169, 176-.
-
Roberts A, Kretzschmar E, Perkins AS, Forman J, Price R, Buonocore L, Kawaoka Y, Rose JK, 1998: Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge[J]. J Virol, 72, 4704-4711.
-
Roberts A, Buonocore L, Price R, Forman J, Rose JK, 1999: Attenuated vesicular stomatitis viruses as vaccine vectors[J]. J Virol, 73, 3723-3732.
-
Rose NF, Marx PA, Luckay A, Nixon DF, Moretto WJ, Donahoe SM, Montefiori D, Roberts A, Buonocore L, Rose JK, 2001: An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants[J]. Cell, 106, 539-549. doi: 10.1016/S0092-8674(01)00482-2
-
Teoh EP, Kukkaro P, Teo EW, Lim AP, Tan TT, 2012: The structural basis for serotype specific neutralization of dengue virus by a human antibody[J]. Sci Transl Med, 4, 139-183.
-
Xie X, Kum DB, Xia H, Luo H, Shan C, Zou J, Muruato AE, Medeiros DBA, Nunes BTD, Dallmeier K, 2018: A single-dose live-attenuated Zika virus vaccine with controlled infection rounds that protects against vertical transmission[J]. Cell Host Microbe, 24, e485-.
-
Xu K, Song Y, Dai L, Zhang Y, Lu X, Xie Y, Zhang H, Cheng T, Wang Q, Huang Q, Bi Y, Liu WJ, Liu W, Li X, Qin C, Shi Y, Yan J, Zhou D, Gao GF, 2018: Recombinant chimpanzee adenovirus vaccine AdC7-M/E protects against Zika virus infection and testis damage[J]. J Virol, 92, e01722-17-. doi: 10.1128/JVI.01722-17
-
Zhao H, Fernandez E, Dowd KA, Speer SD, Platt DJ, Gorman MJ, Govero J, Nelson CA, Pierson TC, Diamond MS, Fremont DH, 2016: Structural basis of Zika virus-specific antibody protection[J]. Cell, 166, 1016-1027. doi: 10.1016/j.cell.2016.07.020